Digital Therapeutics for PTSD and Cannabis Use Disorder
(RISE-C Trial)
Trial Summary
What is the purpose of this trial?
683,000 women are sexually assaulted annually in the United States, half of whom develop chronic posttraumatic stress disorder (PTSD) and thus have markedly increased risk for cannabis use disorder (CUD). The current proposal will test the acceptability, initial efficacy, and mechanisms underlying a novel digital therapeutic targeting risk for PTSD-CUD, which could address the critical need for PTSD-CUD prevention for the 100,000 women who annually present for emergency care after sexual assault. In this research context, the applicant will receive key training in multisite, emergency-care based randomized clinical trials (RCTs), advanced statistical analyses for RCTs and ecological momentary assessment data, biobehavioral mechanisms underlying PTSD-CUD prevention, and professional development, launching her independent research career focused on reducing the public health burden of PTSD-CUD among sexual assault survivors by leveraging digital therapeutics.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Relaxation Control, Relaxation Techniques, Stress Management, Anxiety Reduction Methods, RISE Guide for PTSD and Cannabis Use Disorder?
Is the digital therapeutic treatment for PTSD and cannabis use disorder safe for humans?
Relaxation techniques, including those used in digital therapeutics, have been studied for conditions like PTSD and panic disorder, showing mild therapeutic effects without significant adverse events. However, when cannabis formulations are involved, common side effects include dry mouth, drowsiness, and fatigue, especially with THC.36789
How is the RISE Guide treatment for PTSD and Cannabis Use Disorder different from other treatments?
The RISE Guide treatment is unique because it focuses on digital therapeutic methods like relaxation techniques and stress management, which are non-drug approaches, unlike cannabis-based therapies that involve using cannabis compounds. This treatment offers a novel way to manage symptoms without the use of cannabis, which is often used in other PTSD treatments.18101112
Eligibility Criteria
This trial is for English-speaking women over 18 who have experienced a sexual assault within the last 72 hours and are seeking emergency care. They must use cannabis more than once weekly, have high anxiety sensitivity, own a smartphone with service for over a year, and be able to consent. Exclusions include living with the assailant, being an admitted patient or prisoner, cognitive impairments preventing informed consent, current pregnancy, no fixed address or prior enrollment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a digital therapeutic intervention targeting anxiety sensitivity and PTSD-CUD risk, including a 3-week cognitive behavioral intervention followed by 6 weeks of ecological momentary intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments of PTSD symptoms, anxiety, depression, and cannabis use
Treatment Details
Interventions
- Relaxation Control
- RISE Guide
Relaxation Control is already approved in United States, European Union for the following indications:
- Anxiety
- Stress Management
- PTSD Symptoms Reduction
- Anxiety Disorders
- Stress Relief
- Post-Traumatic Stress Disorder Management
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Nevada, Las Vegas
Lead Sponsor
University of North Carolina, Chapel Hill
Collaborator